Using health outcomes data to inform decision-making healthcare payer perspective

PharmacoEconomics

Volumn 19, Issue SUPPL. 2, 2001, Pages 39-47

  Lancry, P J ^a   O'Connor, R ^b   Stempel, D ^c   Raz, M ^d  

^a National Sickness Fund   (France)

^b Allergy and Immunology Clinic   (United States)

^c VIRGINIA MASON MEDICAL CENTER   (United States)

^d MACCABI HEALTHCARE SERVICES   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIASTHMATIC AGENT; BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUTICASONE PROPIONATE; FORMOTEROL; SALBUTAMOL; SALMETEROL;

ASTHMA; BUDGET; CONFERENCE PAPER; COST BENEFIT ANALYSIS; DATA BASE; DECISION MAKING; DRUG APPROVAL; ECONOMIC EVALUATION; FINANCIAL MANAGEMENT; FRANCE; HEALTH ECONOMICS; HEALTH INSURANCE; HUMAN; ISRAEL; MEDICAL INFORMATION; OUTCOMES RESEARCH; PRIORITY JOURNAL; PROFIT; RESOURCE ALLOCATION; UNITED STATES;

EID: 0034793613     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200119002-00007     Document Type: Conference Paper

References (10)

1. Improving the treatment of patients with asthma: Characteristics of patients with severely symptomatic disease
2. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma
3. Economic impact of salmeterol versus leukotriene modifiers in patients with chronic asthma
4. Cost consequences of dual controller therapy for asthma: Inhaled corticosteroids used concurrently with either salmeterol or leukotriene modifiers
5. The combination of salmeterol and fluticasone improves asthma-related health outcomes at lower cost compared to the combination of inhaled corticosteroids and montelukast
6. Decline in health care use associated with concurrent use of salmeterol and fluticasone propionate